Seeing Is Believing
Currently out of the existing stock ratings of Michael Ryskin, 15 are a HOLD (27.78%), 28 are a BUY (51.85%), 11 are a SELL (20.37%).
Analyst Michael Ryskin, currently employed at BAML, carries an average stock price target met ratio of 77.7% that have a potential upside of 22.03% achieved within 149 days.
Michael Ryskinās has documented 103 price targets and ratings displayed on 15 stocks. The coverage is on Healthcare, ļ»æBasic Materials sectors.
Most recent stock forecast was given on MRVI, Maravai Lifesciences HoldingsĀ at 03-Mar-2025.
Analyst best performing recommendations are on OMIC (SINGULAR GENOMICS SYSTEMS).
The best stock recommendation documented was for OMIC (SINGULAR GENOMICS SYSTEMS) at 6/21/2021. The price target of $780 was fulfilled within 3 days with a profit of $85.2 (12.26%) receiving and performance score of 40.88.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
$10
$7.3 (270.37%)
$10
12 days ago
(20-Mar-2025)
0/3 (0%)
$6.96 (228.95%)
Buy
$7
$4.3 (159.26%)
$7
13 days ago
(19-Mar-2025)
3/11 (27.27%)
$4.02 (134.90%)
133
Buy
$5
$2.3 (85.19%)
$6
2 months 24 days ago
(08-Jan-2025)
3/5 (60%)
$1.78 (55.28%)
30
Buy
$9
$6.3 (233.33%)
1 years 6 days ago
(26-Mar-2024)
0/1 (0%)
$3.79 (72.74%)
Buy
$14
1 years 10 months 16 days ago
(16-May-2023)
0/3 (0%)
$9.22 (192.89%)
Which stock is Michael Ryskin is most bullish on?
Which stock is Michael Ryskin is most reserved on?
What Year was the first public recommendation made by Michael Ryskin?